Company intelligence / Profile preview

Orthogonal Neuroscience

Newton Centre, Massachusetts, United Statespitchbook.com ↗

Ownership: Private
Development stage: Other

Overview

Orthogonal Neuroscience completed a Phase 1, randomized, double-blind, placebo-controlled single ascending dose study evaluating the safety, tolerability, immunogenicity, and pharmacokinetics of intravenous ORT247 in healthy volunteers. The trial was completed as of March 2025; detailed results are not publicly available but preclinical data showed improvement in several disease endpoints for CMT models.

Therapeutic areas: Neurology
Modalities: Monoclonal antibody
Industry: Biotech

Drug pipeline

1 asset

ORT-247

Partnerships

Charcot-Marie-Tooth Association Preclinical Testing Alliance

Beyond the preview

Go deeper on Orthogonal Neuroscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orthogonal Neuroscience.

Explore the full profile